Imagion BiosystemsIBXXF EBITDA Margin % is 0.00% as of Dec. 2025. The stock has 4 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Imagion Biosystems ranks worse than 490195.59% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Imagion Biosystems's EBITDA for the
six
months ended in Dec. 2025 was $-1.65 Mil. Imagion Biosystems's Revenue for the
six
months ended in Dec. 2025 was $0.00 Mil. Therefore, Imagion Biosystems's EBITDA margin for the quarter that ended in Dec. 2025 was 0.00%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Imagion Biosystems EBITDA Margin % Related Terms
Imagion Biosystems EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Imagion Biosystems's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IBXXF vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Imagion Biosystems's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Imagion Biosystems EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Imagion Biosystems's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Imagion Biosystems's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Imagion Biosystems (IBXXF) has a EBITDA Margin % of 0.00% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Imagion Biosystems and its competitors. According to the industry distribution chart, Imagion Biosystems ranks #999999 out of 204 companies in the Medical Diagnostics & Research industry.
Is Imagion Biosystems' EBITDA Margin % too high?
Imagion Biosystems' current EBITDA Margin % is 0.00%. Based on the distribution chart, Imagion Biosystems ranks #999999 out of 204 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Imagion Biosystems' EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Imagion Biosystems ranks #999999 out of 204 companies for EBITDA Margin %. This places Imagion Biosystems in the lower half of its industry. The industry median EBITDA Margin % is 5.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Imagion Biosystems and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Imagion Biosystems's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Imagion Biosystems stock overvalued right now?
Based on GuruFocus' analysis, Imagion Biosystems (IBXXF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.11, compared to a current price of $0.03 — trading 72.7% below its estimated fair value. The current EBITDA Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Imagion Biosystems (IBXXF), the current EBITDA Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Imagion Biosystems Ltd operates in the field of non-invasive detection of specific solid tumor cancers by use of magnetic nanoparticles. Its principal continuing activities consisted of Nanotechnology; Biotechnology; Cancer Diagnostics; and Medical Imaging using Magnetic Resonance and Superparamagnetic Relaxometry. The company only operating segment - Research and Development. Its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics, and medical imaging using Superparamagnetic Relaxometry. In addition, the company is engaged in the research and development of its clinical phase lead product which is intended for the detection and staging of metastatic HER2 breast cancer. The company operates in Australia and the USA, with revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IBXXF has been successfully added to your 